Research suggests that Treg’s ability to suppress cancer development triggered by microbial stimuli heavily relies on IL-10, which can downregulate pro-inflammatory cytokines like IL-6, thereby directly inhibiting Th2 cell activation [213]. This evidence concerns the gene IL10 and cancer.